PBAC's latest decision on Trandolapril with verapamil hydrochloride-sr: Recommended with restriction (2006). Considered for Hypertension in a patient who is stabilised on treatment with trandolapril 4 mg and verapamil hydrochloride sustained release 240 mg.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2006
Submissions
1
2006 → 2006
Eligible population
patients who are stabilised on treatment with trandolapril 4 mg and verapamil hydrochloride sustained release 240 mg
Therapy area
Cardiovascular
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
DBP
Key trials
TV-51-HTN, STAR
Comparator
trandolapril 4 mg and verapamil hydrochloride sustained release 240 mg given as monotherapy
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated